Grifols (GRFS) Cash from Operations Growth (1y) (2011 - 2020)
Grifols (GRFS) Cash from Operations Growth (1y) (2011 - 2020) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
11.07% |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
220.11% |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-39.77% |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
134.19% |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
56.72% |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
57.37% |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
44.79% |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
11.99% |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
-43.50% |
| 10 |
Grifols |
6.05 Bn |
5.09 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2020 |
161.02% |
| Dec 31, 2019 |
-19.52% |
| Mar 31, 2019 |
-267.38% |
| Dec 31, 2018 |
-30.55% |
| Jun 30, 2018 |
-27.16% |
| Mar 31, 2018 |
-26.47% |
| Dec 31, 2017 |
244.90% |
| Dec 31, 2016 |
-42.75% |
| Sep 30, 2016 |
17.97% |
| Mar 31, 2013 |
116,455.24% |
| Dec 31, 2012 |
-3.97% |
| Sep 30, 2012 |
166.91% |
| Jun 30, 2012 |
810.82% |
| Mar 31, 2012 |
-99.82% |
| Dec 31, 2011 |
387.78% |
| Sep 30, 2011 |
196.94% |
